Target intelligence / Profile preview

Peptidyl-prolyl isomerase A (CypA)

Target
CypA
Molecular classification
Enzyme, Peptidyl-prolyl isomerase, Immunophilin
01

Overview

Peptidyl-prolyl isomerase A (CypA), commonly known as cyclophilin A, is an abundant member of the immunophilin family characterized by peptidyl-prolyl cis-trans isomerase activity, which catalyzes the interconversion of proline residues in polypeptide chains and thereby accelerates protein folding[3][5]. CypA plays key roles in protein quality control (chaperone-mediated folding), regulation of intracellular signaling pathways, transcription, cell death, immune response, and angiogenesis[1][3]. As the intracellular receptor for the immunosuppressant cyclosporine, CypA is critical in the suppression of T cell activation during organ transplantation[5]. Cyclophilin A is also implicated in pathologies including viral infection, chronic inflammation, cardiovascular disease, neurodegeneration, and cancer through both its enzymatic and signaling functions[1][3].

Other names
cyclophilin Acyclophilin isomeraserotamase A
02

Mechanism of action

Cyclosporine binds to cyclophilin A, forming a complex that inhibits the phosphatase activity of calcineurin involved in T cell activation and immune response suppression[5].

03

Biological functions

Protein foldingChaperone activitySignal transductionIntracellular signalingApoptosisInflammatory responseAngiogenesisProtein transportTranscription regulation
04

Disease associations

Viral infectionInflammationNeurodegenerative diseaseCancerAtherosclerosisArthritis
05

Safety considerations

Immunosuppression (increased infection risk) due to inhibition of calcineurin pathway by cyclosporine-cyclophilin complex[5].Potential impaired protein folding or chaperone function if cyclophilin activity is inhibited[1].
06

Interacting drugs

Cyclosporine (cyclosporin A)
07

Biomarkers

Cyclophilin A levels in plasma/serum may serve as biomarkers for inflammatory and cardiovascular diseases[3].

Beyond the preview

Go deeper on Peptidyl-prolyl isomerase A (CypA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidyl-prolyl isomerase A (CypA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call